Based on a comparison of coronavirus deaths in 210 countries relative to their population, Peru had the most losses to COVID-19 up until July 13, 2022. As of the same date, the virus had infected over 557.8 million people worldwide, and the number of deaths had totaled more than 6.3 million. Note, however, that COVID-19 test rates can vary per country. Additionally, big differences show up between countries when combining the number of deaths against confirmed COVID-19 cases. The source seemingly does not differentiate between "the Wuhan strain" (2019-nCOV) of COVID-19, "the Kent mutation" (B.1.1.7) that appeared in the UK in late 2020, the 2021 Delta variant (B.1.617.2) from India or the Omicron variant (B.1.1.529) from South Africa.

The difficulties of death figures

This table aims to provide a complete picture on the topic, but it very much relies on data that has become more difficult to compare. As the coronavirus pandemic developed across the world, countries already used different methods to count fatalities, and they sometimes changed them during the course of the pandemic. On April 16, for example, the Chinese city of Wuhan added a 50 percent increase in their death figures to account for community deaths. These deaths occurred outside of hospitals and went unaccounted for so far. The state of New York did something similar two days before, revising their figures with 3,700 new deaths as they started to include “assumed” coronavirus victims. The United Kingdom started counting deaths in care homes and private households on April 29, adjusting their number with about 5,000 new deaths (which were corrected lowered again by the same amount on August 18). This makes an already difficult comparison even more difficult. Belgium, for example, counts suspected coronavirus deaths in their figures, whereas other countries have not done that (yet). This means two things. First, it could have a big impact on both current as well as future figures. On April 16 already, UK health experts stated that if their numbers were corrected for community deaths like in Wuhan, the UK number would change from 205 to “above 300”. This is exactly what happened two weeks later. Second, it is difficult to pinpoint exactly which countries already have “revised” numbers (like Belgium, Wuhan or New York) and which ones do not. One work-around could be to look at (freely accessible) timelines that track the reported daily increase of deaths in certain countries. Several of these are available on our platform, such as for Belgium, Italy and Sweden. A sudden large increase might be an indicator that the domestic sources changed their methodology.

Where are these numbers coming from?

The numbers shown here were collected by Johns Hopkins University, a source that manually checks the data with domestic health authorities. For the majority of countries, this is from national authorities. In some cases, like China, the United States, Canada or Australia, city reports or other various state authorities were consulted. In this statistic, these separately reported numbers were put together. For more information or other freely accessible content, please visit our dedicated Facts and Figures page.

Project Tycho datasets contain case counts for reported disease conditions for countries around the world. The Project Tycho data curation team extracts these case counts from various reputable sources, typically from national or international health authorities, such as the US Centers for Disease Control or the World Health Organization. These original data sources include both open- and restricted-access sources. For restricted-access sources, the Project Tycho team has obtained permission for redistribution from data contributors. All datasets contain case count data that are identical to counts published in the original source and no counts have been modified in any way by the Project Tycho team, except for aggregation of individual case count data into daily counts when that was the best data available for a disease and location. The Project Tycho team has pre-processed datasets by adding new variables, such as standard disease and location identifiers, that improve data interpretability. We also formatted the data into a standard data format. All geographic locations at the country and admin1 level have been represented at the same geographic level as in the data source, provided an ISO code or codes could be identified, unless the data source specifies that the location is listed at an inaccurate geographical level. For more information about decisions made by the curation team, recommended data processing steps, and the data sources used, please see the README that is included in the dataset download ZIP file.

As of October 6, 2022, 11,641 confirmed COVID-19 patients were in hospital in the United Kingdom. The number of COVID patients in hospitals first peaked at over 21.6 thousand on April 12, 2020 and dropped as low as 772 on September 11, 2020. However, the number of patients reached a new peak in the winter of 2020/21 with over 39.2 thousand patients in hospital on January 18, 2021.

The total number of cases in the UK can be found here. For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

Lab-confirmed case counts for England and subnational areas are provided by Public Health England and Office for National Statistics data © Crown copyright and database right 2020. All data on deaths and data for the rest of the UK are provided by the Department of Health and Social Care based on data from NHS England and the devolved administrations. This data is sourced from the UK governments Coronavirus dashboard, and thanks to code developed by Esri UK, the service will refresh when the governments dashboard is updated.To read more information such as the data collection and specific sourced, take a look at the data from the .gov.uk website here

Project Tycho datasets contain case counts for reported disease conditions for countries around the world. The Project Tycho data curation team extracts these case counts from various reputable sources, typically from national or international health authorities, such as the US Centers for Disease Control or the World Health Organization. These original data sources include both open- and restricted-access sources. For restricted-access sources, the Project Tycho team has obtained permission for redistribution from data contributors. All datasets contain case count data that are identical to counts published in the original source and no counts have been modified in any way by the Project Tycho team, except for aggregation of individual case count data into daily counts when that was the best data available for a disease and location. The Project Tycho team has pre-processed datasets by adding new variables, such as standard disease and location identifiers, that improve data interpretability. We also formatted the data into a standard data format. All geographic locations at the country and admin1 level have been represented at the same geographic level as in the data source, provided an ISO code or codes could be identified, unless the data source specifies that the location is listed at an inaccurate geographical level. For more information about decisions made by the curation team, recommended data processing steps, and the data sources used, please see the README that is included in the dataset download ZIP file.

C. difficile infection in patients with a positive specimen taken on day 2 or less of admission (with day 1 as day of admission), and a prior healthcare interaction at the same Trust within the last 28 days. Including all patients aged 2 years and above, diagnosed by one of the following five methods:

Diarrhoeal stools (Bristol Stool types 5-7) where the specimen is C. difficile toxin positive* Toxic megacolon or ileostomy where the specimen is C. difficile toxin positive* Pseudomembranous colitis revealed by lower gastro-intestinal endoscopy or Computed Tomography Colonic histopathology characteristic of C. difficile infection (with or without diarrhoea or toxin detection) on a specimen obtained during endoscopy or colectomy Faecal specimens collected post-mortem where the specimen is C. difficile toxin positive or tissue specimens collected post-mortem where pseudomembranous colitis is revealed or colonic histopathology is characteristic of C. difficile infection

Data is available by Sub ICB (Integrated Care Board) location.

Rationale Surveillance of C. difficile laboratory faecal samples in England and Wales was introduced in 1990 as part of the Public Health Laboratory Service’s voluntary monitoring of infectious diseases. Between 1990 and 2004, there was a rise in the number of C. difficile infections, from less than 3,000 in 1990 to more than 45,000 in 2004. Rates of C. difficile infections also rose over this time period in all age groups ≥40 years old. Due to the increasing incidence of C. difficile infections, the mandatory reporting of C. difficile infection in people aged ≥65 years was introduced in England in January 2004. This was a quarterly aggregate data return reported by NHS acute Trusts comprising data on the number of toxin-positive C. difficile faecal samples. Due to the continued rise of C. difficile infections among the population aged ≥65 years, the C. difficile mandatory surveillance scheme was enhanced in April 2007 to be patient-level and to cover all C. difficile infections in patients aged 2 years and over. Prior healthcare interactions were introduced in April 2017 as a means to determine any prior healthcare interactions from the same Trust. A low value is indicative of a low rate of C. difficile community-onset healthcare-associated cases.

Caveats These data do not provide a basis for decisions on the clinical effectiveness of infection control interventions in individual Trusts: further investigations considering potential confounders would need to be undertaken before this could be done. Nor do these data provide a basis for comparisons between acute Trust or SICBLs. Rate information, using rate calculations as currently defined, is not appropriate for comparison. The counts of infections have not been adjusted to give a standardised rate considering factors such as organisational demographics or case mix. Rate information is of use for comparison of an individual organisation over time. ‘All reported cases’ refers to all toxin-positive results for C. difficile infections that are detected by the Trust whose laboratory processed the specimen. It is important to note that this does not necessarily imply that the infection was acquired there. Confidence intervals for rates are not currently calculated because appropriate methods for comprehensive coverage are being assessed. Cases that the UKHSA’s HCAI Data Capture System attributes to a commissioning hub (such as the national commissioning hub, 13Q, or one of the regional Health & Justice commissioning hubs) are not featured in sub ICB Location dashboards but they do still contribute to the highest spatial level—the England national total. This means the England case total & rates may be slightly higher than the sum of all sub ICB Location cases & rates. IMPORTANT NOTE: CCG calculations for the period between January 2021 and January 2022 have been based on SICBL boundaries. As such, some SICBLs may experience higher or lower rates than expected due to this change. Those SICBLs affected are: Bassetlaw, Glossop, East Leicestershire and Rutland, Lincolnshire, Cambridgeshire and Peterborough, Birmingham and Solihull, Black Country and West Birmingham, and Oundle.

Laboratory confirmed cases of Klebsiella spp. bacteraemia.

Community-onset cases are all those that are not hospital-onset cases.

Hospital-onset is determined on patient location, date of admission, date of specimen, and patient category. Hospital onset is only indicative for cases where NHS patient specimens are taken on the third day of admission onwards (e.g., day three when day one equals day of admission) at an acute trust (including cases with unspecified specimen location) for inpatients, day patients, emergency assessment, or unspecified patient category. Records with a missing admission date (where the specimen location is acute trust or missing and the patient category is inpatient, day patient, emergency assessment, or unspecified) are also included. Other cases may have hospital onset, but not in acute trusts.Data is available by Sub ICB (Integrated Care Board) location.

Rationale In April 2017, the enhanced patient-level mandatory surveillance scheme was extended to include Klebsiella spp. bacteraemia due to the high national total of Gram-negative bacteraemias. The mandatory surveillance of Klebsiella spp. bacteraemia supports the Secretary of State for Health's ambition to reduce healthcare-associated Gram-negative bacteraemia by 50% by 2021.

https://improvement.nhs.uk/documents/822/2017-03-15_Letter_-_GNBSI_edits.pdf

A low value is indicative of a low rate of Klebsiella spp. bacteraemia.

Caveats These data do not provide a basis for decisions on the clinical effectiveness of infection control interventions in individual Trusts: further investigations considering potential confounders would need to be undertaken before this could be done. Nor do these data provide a basis for comparisons between acute Trust or SICBLs. Rate information, using rate calculations as currently defined, is not appropriate for comparison. The counts of infections have not been adjusted to give a standardised rate considering factors such as organisational demographics or case mix. Rate information is of use for comparison of an individual organisation over time.

‘All reported cases’ refers to all Klebsiella spp.-positive blood cultures reported by the Trust whose laboratory processes the specimen. It is important to note that this does not necessarily imply that the infection was acquired there. Confidence intervals for rates are not currently calculated because appropriate methods for comprehensive coverage are being assessed.

Cases that the UKHSA’s HCAI Data Capture System attributes to a commissioning hub (such as the national commissioning hub, 13Q, or one of the regional Health & Justice commissioning hubs) are not featured in sub ICB Location dashboards but they do still contribute to the highest spatial level—the England national total. This means the England case total & rates may be slightly higher than the sum of all sub ICB Location cases & rates.

IMPORTANT NOTE: SICBL calculations for the period between January 2021 and January 2022 have been based on SICBL boundaries. As such, some SICBLs may experience higher or lower rates than expected due to this change. Those SICBLs affected are: Bassetlaw, Glossop, East Leicestershire and Rutland, Lincolnshire, Cambridgeshire and Peterborough, Birmingham and Solihull, Black Country and West Birmingham, and Oundle.

As of November 24, 2024 there were over 274 million confirmed cases of coronavirus (COVID-19) across the whole of Europe since the first confirmed cases in France in January 2020. France has been the worst affected country in Europe with 39,028,437 confirmed cases, followed by Germany with 38,437,756 cases. Italy and the UK have approximately 26.8 million and 25 million cases respectively. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

Laboratory confirmed cases of MRSA bacteraemia. Community-onset cases are all those that are not hospital-onset cases. Hospital-onset is determined by patient location, date of admission, date of specimen, and patient category. Hospital onset is only indicative for cases where NHS patient specimens are taken on the third day of admission onwards (e.g., day three when day one equals the day of admission) at an acute trust (including cases with unspecified specimen location) for inpatients, day patients, emergency assessment, or unspecified patient category. Records with a missing admission date (where the specimen location is acute trust or missing and the patient category is inpatient, day patient, emergency assessment, or unspecified) are also included. Other cases may have hospital onset, but not in acute trusts.

Data is available by Sub ICB (Integrated Care Board) location.

Rationale A long-running voluntary surveillance scheme of laboratory-reported cases of Staphylococcus aureus bacteraemia showed increasing incidence of meticillin-resistant S. aureus (MRSA) infections in England, Wales, and Northern Ireland in the 1990s. This generated both media and public interest. In response, the Department of Health (DH) in England introduced a mandatory surveillance scheme for S. aureus bacteraemias in April 2001, which included data on the number of cases that were due to MRSA. In October 2005, the mandatory surveillance scheme for MRSA bacteraemias was enhanced to collect patient-level data. Additionally, all NHS organisations reporting cases of MRSA bacteraemia from 1 April 2013 were required to complete a Post Infection Review (PIR). This process was commenced to support the delivery of zero tolerance on MRSA bacteraemia, as set out by NHS England in the Planning Guidance Everyone counts: Planning for Patients 2013/14. A PIR is undertaken after all MRSA bacteraemias with the purpose of identifying how a case occurred, to identify actions by local healthcare teams which will prevent a reoccurrence, and to identify the organisation best placed to ensure improvements are made (this is known as “assigning” a case to an organisation). From 1 April 2018, the PIR process changed from being applied by all trusts to trusts identified as having high rates of MRSA. For more information, please see MRSA Guidance: Post Infection Review. A low value is indicative of a low rate of MRSA.

Source of numerator UK Health Security Agency (UKHSA), Healthcare Associated Infection Data Capture System (HCAI DCS) Mandatory Surveillance

Source of denominator Office for National Statistics (ONS), Mid-year population estimates

Caveats These data do not provide a basis for decisions on the clinical effectiveness of infection control interventions in individual Trusts: further investigations considering potential confounders would need to be undertaken before this could be done.

Nor do these data provide a basis for comparisons between acute Trust or SICBLs. Rate information, using rate calculations as currently defined, is not appropriate for comparison. The counts of infections have not been adjusted to give a standardised rate considering factors such as organisational demographics or case mix. Rate information is of use for comparison of an individual organisation over time.

‘All reported cases’ refers to all MRSA-positive blood cultures reported by the Trust whose laboratory processes the specimen. It is important to note that this does not necessarily imply that the infection was acquired there.

Confidence intervals for rates are not currently calculated because appropriate methods for comprehensive coverage are being assessed.

Cases that the UKHSA’s HCAI Data Capture System attributes to a commissioning hub (such as the national commissioning hub, 13Q, or one of the regional Health & Justice commissioning hubs) are not featured in sub ICB Location dashboards but they do still contribute to the highest spatial level—the England national total. This means the England case total & rates may be slightly higher than the sum of all sub ICB Location cases & rates.

IMPORTANT NOTE: SICBL calculations for the period between January 2021 and January 2022 have been based on SICBL boundaries. As such some SICBLs may experience higher or lower rates than expected due to this change. Those SICBLs affected are; Bassetlaw, Glossop, East Leicestershire and Rutland, Lincolnshire, Cambridgeshire and Peterborough, Birmingham and Solihull, Black Country and West Birmingham and Oundle.

On March 4, 2020, the first death as a result of coronavirus (COVID-19) was recorded in the United Kingdom (UK). The number of deaths in the UK has increased significantly since then. As of January 13, 2023, the number of confirmed deaths due to coronavirus in the UK amounted to 202,157. On January 21, 2021, 1,370 deaths were recorded, which was the highest total in single day in the UK since the outbreak began.

Number of deaths among highest in Europe
The UK has had the highest number of deaths from coronavirus in western Europe. In terms of rate of coronavirus deaths, the UK has recorded 297.8 deaths per 100,000 population.

Cases in the UK The number of confirmed cases of coronavirus in the UK was 24,243,393 as of January 13, 2023. The South East has the highest number of first-episode confirmed cases of the virus in the UK with 3,123,050 cases, while London and the North West have 2,912,859 and 2,580,090 confirmed cases respectively. As of January 16, the UK has had 50 new cases per 100,000 in the last seven days.

For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

As of June 13, 2023, there have been almost 768 million cases of coronavirus (COVID-19) worldwide. The disease has impacted almost every country and territory in the world, with the United States confirming around 16 percent of all global cases.

COVID-19: An unprecedented crisis Health systems around the world were initially overwhelmed by the number of coronavirus cases, and even the richest and most prepared countries struggled. In the most vulnerable countries, millions of people lacked access to critical life-saving supplies, such as test kits, face masks, and respirators. However, several vaccines have been approved for use, and more than 13 billion vaccine doses had already been administered worldwide as of March 2023.

The coronavirus in the United Kingdom Over 202 thousand people have died from COVID-19 in the UK, which is the highest number in Europe. The tireless work of the National Health Service (NHS) has been applauded, but the country’s response to the crisis has drawn criticism. The UK was slow to start widespread testing, and the launch of a COVID-19 contact tracing app was delayed by months. However, the UK’s rapid vaccine rollout has been a success story, and around 53.7 million people had received at least one vaccine dose as of July 13, 2022.

Provisional counts of the number of deaths registered in England and Wales, including deaths involving coronavirus (COVID-19), by local authority, health board and place of death in the latest weeks for which data are available. The occurrence tabs in the 2021 edition of this dataset were updated for the last time on 25 October 2022.

Data published on potential COVID-19 symptoms reported through NHS Pathways and 111 online Dashboard shows the total number of NHS Pathways triages through 111 and 999, and online assessments in 111 online which have received a potential COVID-19 final disposition. This data is based on potential COVID-19 symptoms reported by members of the public to NHS Pathways through NHS 111 or 999 and 111 online, and is not based on the outcomes of tests for coronavirus. This is not a count of people.

Project Tycho datasets contain case counts for reported disease conditions for countries around the world. The Project Tycho data curation team extracts these case counts from various reputable sources, typically from national or international health authorities, such as the US Centers for Disease Control or the World Health Organization. These original data sources include both open- and restricted-access sources. For restricted-access sources, the Project Tycho team has obtained permission for redistribution from data contributors. All datasets contain case count data that are identical to counts published in the original source and no counts have been modified in any way by the Project Tycho team. The Project Tycho team has pre-processed datasets by adding new variables, such as standard disease and location identifiers, that improve data interpretabilty. We also formatted the data into a standard data format. Each Project Tycho dataset contains case counts for a specific condition (e.g. measles) and for a specific country (e.g. The United States). Case counts are reported per time interval. In addition to case counts, datsets include information about these counts (attributes), such as the location, age group, subpopulation, diagnostic certainty, place of aquisition, and the source from which we extracted case counts. One dataset can include many series of case count time intervals, such as "US measles cases as reported by CDC", or "US measles cases reported by WHO", or "US measles cases that originated abroad", etc. Depending on the intended use of a dataset, we recommend a few data processing steps before analysis:

Analyze missing data: Project Tycho datasets do not inlcude time intervals for which no case count was reported (for many datasets, time series of case counts are incomplete, due to incompleteness of source documents) and users will need to add time intervals for which no count value is available. Project Tycho datasets do include time intervals for which a case count value of zero was reported. Separate cumulative from non-cumulative time interval series. Case count time series in Project Tycho datasets can be "cumulative" or "fixed-intervals". Cumulative case count time series consist of overlapping case count intervals starting on the same date, but ending on different dates. For example, each interval in a cumulative count time series can start on January 1st, but end on January 7th, 14th, 21st, etc. It is common practice among public health agencies to report cases for cumulative time intervals. Case count series with fixed time intervals consist of mutually exxclusive time intervals that all start and end on different dates and all have identical length (day, week, month, year). Given the different nature of these two types of case count data, we indicated this with an attribute for each count value, named "PartOfCumulativeCountSeries".

Laboratory confirmed cases of P. aeruginosa bacteraemia. Community-onset cases are all those that are not hospital-onset cases. Hospital-onset is determined by patient location, date of admission, date of specimen, and patient category. Hospital onset is only indicative for cases where NHS patient specimens are taken on the third day of admission onwards (e.g., day three when day one equals the day of admission) at an acute trust (including cases with unspecified specimen location) for inpatients, day patients, emergency assessment, or unspecified patient category. Records with a missing admission date (where the specimen location is acute trust or missing and the patient category is inpatient, day patient, emergency assessment, or unspecified) are also included. Other cases may have hospital onset, but not in acute trusts.

Data is available by Sub ICB (Integrated Care Board) location.

Rationale Monitoring and reporting on Pseudomonas aeruginosa bacteraemia infections are crucial due to the significant morbidity and mortality associated with these infections, particularly in hospital settings. P. aeruginosa is a major nosocomial pathogen that can cause severe infections, especially in immunocompromised patients, those with severe burns, or individuals on mechanical ventilation (source). The pathogen's increasing resistance to multiple antibiotics further complicates treatment options, making early detection and appropriate management essential (source). By closely monitoring these infections, healthcare providers can implement timely infection control measures, reduce the spread of this opportunistic pathogen, and improve patient outcomes (source). Additionally, reporting helps in understanding the epidemiology of P. aeruginosa bacteraemia, guiding public health interventions and informing antibiotic stewardship programs (source).

Caveats These data do not provide a basis for decisions on the clinical effectiveness of infection control interventions in individual Trusts: further investigations considering potential confounders would need to be undertaken before this could be done. Nor do these data provide a basis for comparisons between acute Trust or sub ICB location (SICBL). Rate information, using rate calculations as currently defined, is not appropriate for comparison. The counts of infections have not been adjusted to give a standardised rate considering factors such as organisational demographics or case mix. Rate information is of use for comparison of an individual organisation over time. ‘All reported cases’ refers to all P. aeruginosa-positive blood cultures reported by the Trust whose laboratory processes the specimen. It is important to note that this does not necessarily imply that the infection was acquired there. Confidence intervals for rates are not currently calculated because appropriate methods for comprehensive coverage are being assessed. Cases that the UKHSA’s HCAI Data Capture System attributes to a commissioning hub (such as the national commissioning hub, 13Q, or one of the regional Health & Justice commissioning hubs) are not featured in sub ICB Location dashboards but they do still contribute to the highest spatial level—the England national total. This means the England case total & rates may be slightly higher than the sum of all sub ICB Location cases & rates. IMPORTANT NOTE: SICBL calculations for the period between January 2021 and January 2022 have been based on Sub-ICB boundaries. As such some SICBLs may experience higher or lower rates than expected due to this change. Those SICBLs affected are: Bassetlaw, Glossop, East Leicestershire and Rutland, Lincolnshire, Cambridgeshire and Peterborough, Birmingham and Solihull, Black Country and West Birmingham, and Oundle.

As of May 2, 2023, the outbreak of the coronavirus disease (COVID-19) had been confirmed in almost every country in the world. The virus had infected over 687 million people worldwide, and the number of deaths had reached almost 6.87 million. The most severely affected countries include the U.S., India, and Brazil.

COVID-19: background information COVID-19 is a novel coronavirus that had not previously been identified in humans. The first case was detected in the Hubei province of China at the end of December 2019. The virus is highly transmissible and coughing and sneezing are the most common forms of transmission, which is similar to the outbreak of the SARS coronavirus that began in 2002 and was thought to have spread via cough and sneeze droplets expelled into the air by infected persons.

Naming the coronavirus disease Coronaviruses are a group of viruses that can be transmitted between animals and people, causing illnesses that may range from the common cold to more severe respiratory syndromes. In February 2020, the International Committee on Taxonomy of Viruses and the World Health Organization announced official names for both the virus and the disease it causes: SARS-CoV-2 and COVID-19, respectively. The name of the disease is derived from the words corona, virus, and disease, while the number 19 represents the year that it emerged.

Provisional counts of the number of deaths registered in England and Wales, by age, sex, region and Index of Multiple Deprivation (IMD), in the latest weeks for which data are available.

Provisional counts of the number of deaths and age-standardised mortality rates involving the coronavirus (COVID-19), by occupational groups, for deaths registered between 9 March and 28 December 2020 in England and Wales. Figures are provided for males and females.